# A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions

> **NCT00865241** · PHASE1 · COMPLETED · sponsor: **Actavis Inc.** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg
- **DRUG:** CLUCOVANCE® 5 mg/500 mg Tablets, single dose

## Key facts

- **NCT ID:** NCT00865241
- **Lead sponsor:** Actavis Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** 2002-11
- **Final completion:** 2002-11
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2010-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00865241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00865241, "A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00865241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*